Klaus Beck, Vice President, Medical Affairs, talks about the creation of MSD’s new Innovation and Development Hub in Zurich.
In focus: skin cancer prevention
In Switzerland, around 2800 people contract melanoma (black skin cancer) every year. Despite major progress in treatment, the disease is fatal for some patients. Early detection of skin cancer can save lives.
Prevention of skin cancer: How to protect yourself 
Inventing for Life
MSD is one of the world's leading research-based biopharmaceutical companies. For more than 125 years, we have been developing and providing medicines and vaccines that can improve the health of people and animals and enable them to live better lives.
We strive to provide hope to people with cancer.
MSD operates one of the world's largest and fastest growing clinical research programs in the field of immune-oncology. In Switzerland, we are currently conducting 26 clinical trials (as of 03/2020) in various types of cancer.
Disease prevention
For more than 100 years, we have been researching and developing innovative vaccines to help prevent certain diseases in children, adolescents and adults.
Vaccines: Our History, Our Legacy
Health protection through vaccination
Research for innovation
Switzerland is one of more than fifty countries in which MSD conducts clinical research. The active substances discovered in the global MSD Research Laboratories are tested in Switzerland in all phases of clinical research.
